Stefania Gagliardi

TL;DR: Four independent approaches that did not start from bafilomycin have led to the discovery of a different class of V-ATPase inhibitors, among which 4-(2,6-dichlorobenzoyl)amino-2-trifluoromethyl(benzoimidazol-1-yl)acetyl morpholine was the most effective in preventing bone resorption in an ovariectomized rat model of osteoporosis.

TL;DR: In this paper, a continuous flow reactor was used to react carbonyl compounds with Grignard reagents at room temperature in an efficient and safe manner, and the results showed that a small collection of secondary and tertiary alcohols were obtained using the set-up protocol.

TL;DR: The validity of the osteoclast proton pump as a useful molecular target to produce novel inhibitors of bone resorption, potentially useful as antiosteporotic agents is supported.

TL;DR: In vitro and in vivo data are presented for (E)-3-(4-fluoro-3-hydroxy-phenyl)-N-naphthalen-1-yl-acrylamide 22, one of the most interesting compounds, able to attenuate opening of the mPTP and limit reperfusion injury in a rabbit model of acute myocardial infarction.

TL;DR: 31 derivatives of bafilomycin A1 were synthesized and tested for their ability to inhibit differentially the V-ATPase-driven proton transport in membrane vesicles derived from chicken osteoclasts and bovine chromaffin granules.